CXCR4-related Disease, Metastasis, Positron Emission Tomography, Tumor
Conditions
Keywords
PET/CT, Chemokine receptor 4, Pentixafor, Pentixather
Brief summary
To evaluate the potential usefulness of 68Ga/18F-Pentixafor/Pentixather positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.
Detailed description
Subjects with various CXCR4-related disease patients underwent 68Ga/18F-Pentixafor/Pentixather PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 68Ga/18F-Pentixafor/Pentixather PET/CT were calculated.
Interventions
DIAGNOSTIC_TESTCXCR4 PET/CT Imaging
Each subject receive a single intravenous injection of 68Ga/18F-Pentixafor/Pentixather, and undergo PET/CT imaging within the specificed time.
Sponsors
Tianjin Medical University
Tianjin Medical University General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients * 18F-FDG PET/CT within two weeks * signed written consent.
Exclusion criteria
* pregnancy * breastfeeding * known allergy against Pentixafor
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Standardized uptake value (SUV) | 30 days | Standardized uptake value (SUV) of FAPI for each target lesion of subject or suspected primary tumor or/and metastasis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic efficacy | 30 days | The sensitivity, specificity and accuracy of FAPI PET/CT were calculated. |
Countries
China
Contacts
CONTACTHaonan Yu, MD
CONTACTShaobo Yao, PhD
Outcome results
None listed